<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Rapid COVID-19 diagnostics with CMOS-integrated single-molecule field-effect transistors</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/01/2020</AwardEffectiveDate>
<AwardExpirationDate>03/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>255678.00</AwardTotalIntnAmount>
<AwardAmount>255678</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Alastair Monk</SignBlockName>
<PO_EMAI>amonk@nsf.gov</PO_EMAI>
<PO_PHON>7032924392</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact / commercial potential of this Small Business Innovation Research (SBIR) Phase I Project is to reduce time-to-diagnosis for COVID-19 through the development of a novel all-electronic single-molecule molecular diagnostics platform.  The proposed technology has the potential to eliminate sample processing bottlenecks that have resulted in delayed diagnosis.  The system's form-factor is compact and widely deployable, enabling point-of-care and/or near-point-of-care test settings.  The system comprise a reader unit and disposable test-chips.  This will enable rapid testing. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project will advance a prototype of a all-electronic single-molecule molecular diagnostics platform and demonstrate direct detection of SARS-CoV-2 RNA.  Prototype completion will involve integrating our single-molecule biosensors onto application-specific integrated circuitry and optimizing the chemical functionalization process to enable single-molecule detection.  Processes will be developed for controlled RNA fragmentation, required for direct RNA detection.  Direct detection will eliminate the need to perform extensive enzymatic processing required in quantitative Reverse-Transcription Polymerase-Chain-Reaction (qRT-PCR)-based systems.  Efficient data processing algorithms will be designed and implemented in the data acquisition hardware to accelerate diagnosis.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>09/01/2020</MinAmdLetterDate>
<MaxAmdLetterDate>12/10/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2031181</AwardID>
<Investigator>
<FirstName>Steven</FirstName>
<LastName>Warren</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Steven Warren</PI_FULL_NAME>
<EmailAddress>swarren@quicksilverbiosciences.com</EmailAddress>
<PI_PHON>9143932633</PI_PHON>
<NSF_ID>000797651</NSF_ID>
<StartDate>09/01/2020</StartDate>
<EndDate>12/10/2020</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Erik</FirstName>
<LastName>Young</LastName>
<PI_MID_INIT>F</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Erik F Young</PI_FULL_NAME>
<EmailAddress>efy@quicksilverbiosciences.com</EmailAddress>
<PI_PHON>9173341824</PI_PHON>
<NSF_ID>000844050</NSF_ID>
<StartDate>12/10/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>QUICKSILVER BIOSCIENCES, INC.</Name>
<CityName>NEW YORK</CityName>
<ZipCode>100272510</ZipCode>
<PhoneNumber>9146438717</PhoneNumber>
<StreetAddress>1361 Amsterdam Avenue</StreetAddress>
<StreetAddress2><![CDATA[Suite 340]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<StateCode>NY</StateCode>
<CONGRESSDISTRICT>13</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>NY13</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>081250499</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>QUICKSILVER BIOSCIENCES, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[QUICKSILVER BIOSCIENCES, INC.]]></Name>
<CityName>New York</CityName>
<StateCode>NY</StateCode>
<ZipCode>100272510</ZipCode>
<StreetAddress><![CDATA[1361 Amsterdam Ave - Suite 340]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>13</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>NY13</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>066E</Code>
<Text>INSTRUMENTATION &amp; DIAGNOSTICS</Text>
</ProgramReference>
<ProgramReference>
<Code>090E</Code>
<Text>Chem/Bio and Physical Diagnostics</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<ProgramReference>
<Code>8033</Code>
<Text>Hardware Software Integration</Text>
</ProgramReference>
<ProgramReference>
<Code>8035</Code>
<Text>Hardware Devices</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~255678</FUND_OBLG>
</Award>
</rootTag>
